Role of lipid emulsion in organophosphate compound poisoning
Phase 2
Completed
- Conditions
- Health Condition 1: T600- Toxic effect of organophosphate and carbamate insecticides
- Registration Number
- CTRI/2019/04/018699
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.History of consumption of organophosphate compound.
2.Clinical manifestations of moderate or severe organophosphorus compound poisoning as per Peradeniya Severity Score.
3.Informed consent from the patient or next kin.
Exclusion Criteria
1.Where the compound ingested could not be identified.
2.History of combined poisoning with a non-OP compound.
3.All other patients not fitting in the organophosphate symptom complex.
4.Patients having underlying kidney and liver ailments.
5.History suggestive of acute pancreatitis in the past.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the change in amount of atropine dose used after delivering extended doses of lipid emulsion in OP poisoned individuals. In test arm we will give 20% of 100ml Lipid emulsion over 1 hour followed by an infusion of the same over 6 hours. In control arm we will give 100ml of NS over 1 hour followed by 100ml NS over 6 hours.Timepoint: After 48 hours total dose of atropine required will be calculated
- Secondary Outcome Measures
Name Time Method 1. Hemodynamic parameters (pulse rate, systolic, diastolic blood pressures, mean arterial pressure and respiratory rate) <br/ ><br>2.Duration of hospitalization <br/ ><br>3.Duration of mechanical ventilation required <br/ ><br>4.In-hospital 7 days mortality <br/ ><br>5.28th day mortality <br/ ><br>Timepoint: At 0 hour, 6 hours, 24 hours and 48 hours